A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Immune System Diseases Clinical Trial

Official title:

Phase 2 Study BRIDGING PRE-TRANSPLANT INFLAMMATORY DAMPENING for PRIMARY IMMUNE REGULATORY DISORDERS (BRIDGE Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05787574
• Other study ID #: 23-040
• Secondary ID: R01FD007829
• Status: Recruiting
• Phase: Phase 2
• Start date: March 15, 2023
• Est. completion date: March 2027

Study information

• Verified date: May 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: Joseph Oved, MD
• Phone: 646-888-3314
• Email: ovedj[@]mskcc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells.

"Funding Source - FDA OOPD"

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 39
• Est. completion date: March 2027
• Est. primary completion date: March 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients receiving first allo-HCT for the following immunologic conditions:

• Primary Immune Regulatory Disorder with or without a genetic lesion as defined by the Primary Immune Deficiency Treatment Consortium (PIDTC)

• Patients with autoinflammatory disorders evidenced by cytokine or inflammation assays with at least 1.5x ULN of measured cytokines and/or an elevated ferritin or ESR > 2 ULN

• For inclusion on the emapalumab group, the lesion must be isolated to the IFN? pathway (or mediators thereof) with an elevated CXCL9 >1.5 ULN OR sIL2R >1.5 ULN (or already controlled on immune modulation, provided that CXCL9 or sIL2R levels were elevated prior to initiation of immune modulation). Inclusion on the Fludarabine/dexamethasone group requires inflammation (as defined above) other than an isolated IFN? pathway

• Able to tolerate cytoreduction (based on adequate organ function as described below)

• Patients of any age can enroll so long as they meet other inclusion criteria:

• Adequate organ function is required, defined as follows:

• Hepatic: Serum bilirubin = 2 mg/dL, unless benign congenital hyperbilirubinemia. Patients with hyperbilirubinemia related to paroxysmal nocturnal hemoglobinuria or other hemolytic disorders related to their PIRD diagnosis are eligible.

• Hepatic: AST, ALT, and alkaline phosphatase < 2.5 times the upper limit of normal unless thought to be disease-related. Investigator will need to perform clinically indicated evaluations to assess if disease related or intrinsic liver disease. Additional testing may be done if clinically indicated, after the pre-transplant immune prophase and prior to start of conditioning as this will provide additional data to confirm disease related versus intrinsic liver dysfunction.

• Renal: serum creatinine <1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.

• Normal GFR by Age

• Cardiac: LVEF = 50% by MUGA or resting echocardiogram.

• Pulmonary: Pulmonary function testing (FEV1 and corrected DLCO) = 50% predicted (pediatric patients unable to complete PFTs will need oxygen saturation as recorded by pulse oximetry of =92% on room air).

• Adequate performance status:

• Age = 16 years: ECOG = 1 or Karnofsky 70%

• Age < 16 years: Lansky 70%

• Each patient must be willing to participate as a research subject and must sign an informed consent form or legal guardian with assent as appropriate.

Exclusion Criteria:

• Uncontrolled infection at the time of enrollment.

• Patients who have undergone previous allo-HCT.

• Patient seropositivity for HIV I/II and/or HTLV I/II.

• Females who are pregnant or breastfeeding.

• Patients unwilling to use contraception during the study period.

• Patient or parent or guardian unable to give informed consent or unable to comply with the treatment protocol including research tests.

Donor Inclusion Criteria:

• Related Donors:

• 8/8 or 7/8 HLA matched at A, B, C, and DRB1 loci, as tested by DNA analysis.

• Haploidentical donors at A, B, C and DRB1 loci, as tested by DNA analysis

• Unrelated Donors:

o 8/8 or 7/8 matched at A, B, C, and DRB1 loci, as tested by DNA analysis.

• Able to provide informed consent for the donation process per institutional standards.

• Meet standard criteria for donor collection (e.g. National Marrow Donor Program Guidelines or collecting center guidelines as approved by treating physician).

Related Conditions & MeSH terms

• Autoimmune Lymphoproliferative
• Immune System Diseases

Intervention

Drug:
• Emapalumab
Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.
• Fludarabine and Dexamethasone
Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.

Procedure:
• Stem Cell Transplant
Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)	Commack	New York
United States	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison	New York
United States	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Rockville Centre	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Sobi, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Engraftment	is defined as the first of three days of absolute neutrophil count >500k/µL and the first of seven days of platelets >20,000/µL in the absence of transfusional support.	1 year
Secondary	Determine Overall Survival (OS)	the duration of time between HCT and death due to any cause	5 years

External Links

•   Memorial Sloan Kettering Cancer Center